Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Nathan

Showing results (31-40 of 129) with videos related to

Pageof 13
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 13, 2019
Expert Elicitation to Inform a Cost-Effectiveness Analysis of Screening for Renal CancerSabrina H Rossi, Christopher Blick, Paul Nathan, et al.
Pediatric Blood & Cancer|February 7, 2025
Comment on: Incidence of Adrenal Insufficiency in Patients with High-Risk Neuroblastoma: A Single-Institution AnalysisDaniel A Morgenstern, Sarah Cohen-Gogo, Denise Connolly, et al.
European Urology|December 18, 2013
Assessing the response to targeted therapies in renal cell carcinoma: technical insights and practical considerationsAxel Bex, Laure Fournier, Nathalie Lassau, et al.
Cureus|October 27, 2025
Gastrointestinal Dysautonomia: A Rare Immune-Related Adverse Event That Requires Early Recognition and High-Dose ImmunosuppressionBenjamin Norton, Stefan Sennfalt, Ross Nortley, et al.
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|July 27, 2023
Childhood bone tumours in primary care: helping GPs to identify 'the needle in the haystack'Dhurgshaarna Shanmugavadivel, Jo-Fen Liu, Ashley Ball-Gamble, et al.
Pharmacoeconomics - Open|January 26, 2019
Cost Effectiveness of Avelumab for Metastatic Merkel Cell CarcinomaAsh Bullement, Paul Nathan, Anna Willis, et al.
American Journal of Obstetrics and Gynecology|January 31, 2012
Delivery of monochorionic twins in the absence of complications: analysis of neonatal outcomes and costsAmy Elizabeth Sullivan, Paul Nathan Hopkins, Hsin-Yi Weng, et al.
European Journal of Cancer (Oxford, England : 1990)|September 30, 2016
Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysisBernard Escudier, Vincent Molinie, Sergio Bracarda, et al.
Clinical Epigenetics|September 17, 2013
Methylation profiling and evaluation of demethylating therapy in renal cell carcinomaChristopher J Ricketts, Mark R Morris, Dean Gentle, et al.
European Journal of Cancer (Oxford, England : 1990)|November 10, 2012
The hazards of cross comparing the drug toxicity results from different trials in metastatic renal cancer: in response to a letter from Dr. Catalá-LópezThomas Powles, Naveed Sarwar, Rob Jones, et al.
Pageof 13

Showing results (31-40 of 129) with videos related to

Sort By:
Pageof 13
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 13, 2019
Expert Elicitation to Inform a Cost-Effectiveness Analysis of Screening for Renal CancerSabrina H Rossi, Christopher Blick, Paul Nathan, et al.
Pediatric Blood & Cancer|February 7, 2025
Comment on: Incidence of Adrenal Insufficiency in Patients with High-Risk Neuroblastoma: A Single-Institution AnalysisDaniel A Morgenstern, Sarah Cohen-Gogo, Denise Connolly, et al.
European Urology|December 18, 2013
Assessing the response to targeted therapies in renal cell carcinoma: technical insights and practical considerationsAxel Bex, Laure Fournier, Nathalie Lassau, et al.
Cureus|October 27, 2025
Gastrointestinal Dysautonomia: A Rare Immune-Related Adverse Event That Requires Early Recognition and High-Dose ImmunosuppressionBenjamin Norton, Stefan Sennfalt, Ross Nortley, et al.
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|July 27, 2023
Childhood bone tumours in primary care: helping GPs to identify 'the needle in the haystack'Dhurgshaarna Shanmugavadivel, Jo-Fen Liu, Ashley Ball-Gamble, et al.
Pharmacoeconomics - Open|January 26, 2019
Cost Effectiveness of Avelumab for Metastatic Merkel Cell CarcinomaAsh Bullement, Paul Nathan, Anna Willis, et al.
American Journal of Obstetrics and Gynecology|January 31, 2012
Delivery of monochorionic twins in the absence of complications: analysis of neonatal outcomes and costsAmy Elizabeth Sullivan, Paul Nathan Hopkins, Hsin-Yi Weng, et al.
European Journal of Cancer (Oxford, England : 1990)|September 30, 2016
Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysisBernard Escudier, Vincent Molinie, Sergio Bracarda, et al.
Clinical Epigenetics|September 17, 2013
Methylation profiling and evaluation of demethylating therapy in renal cell carcinomaChristopher J Ricketts, Mark R Morris, Dean Gentle, et al.
European Journal of Cancer (Oxford, England : 1990)|November 10, 2012
The hazards of cross comparing the drug toxicity results from different trials in metastatic renal cancer: in response to a letter from Dr. Catalá-LópezThomas Powles, Naveed Sarwar, Rob Jones, et al.
Pageof 13